NCT02884037View on ClinicalTrials.gov

Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

October 31, 2016

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Rifaximin group 1

Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals

Trial Locations (1)

Unknown

Nasser H Mousa,MD,[email protected]. +201227029213, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT02884037 - Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) | Biotech Hunter | Biotech Hunter